Posted by Michael Wonder on 28 Mar 2026
Egetis announces FDA acceptance and priority review of NDA for Emcitate (tiratricol) for MCT8 feficiency
27 March 2026 - Egetis Therapeutics today announced that the US FDA has accepted the filing of its new drug application for Emcitate (tiratricol) for the treatment of MCT8 deficiency. Egetis completed the rolling new drug application in January 2026.
The application has been granted priority review and assigned a PDUFA target action date, or FDA decision date, of 28 September 2026.
